Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Bosulif“
Suchtreffer
Begriffe & Kennungen
Bosulif · 4.8 · Blood and lymphatic system disorders
Eintrag öffnenBosulif · 4.8 · Blood and lymphatic system disorders Of the 372 (27.1%) adult patients with reports of adverse reactions of an
Eintrag öffnenBosulif · 4.8 · Cardiac disorders Among 1372 patients, cardiac failure occurred in 50 (3.6%) patients and cardiac ischaemic ev
Eintrag öffnenBosulif · 4.8 · Description of selected adverse reactions
Eintrag öffnenBosulif · 4.8 · Gastrointestinal disorders Gastrointestinal disorders of diarrhoea, vomiting and nausea occurred in 81.8%, 56.
Eintrag öffnenBosulif · 4.8 · Gastrointestinal disorders Of the 1 103 (80.4%) patients that experienced diarrhoea, 14 patients discontinued
Eintrag öffnenBosulif · 4.8 · Hepatitis B reactivation Hepatitis B reactivation has been reported in association with BCR-ABL TKIs. Some cas
Eintrag öffnenBosulif · 4.8 · Hepatobiliary disorders Of the 55 participants, the incidence based on laboratory data of ALT and AST increase
Eintrag öffnenBosulif · 4.8 · Infections and infestations Very common Nasopharyngitis Respiratory tract infectiona Common Influenzab Pneumon
Eintrag öffnenBosulif · 4.8 · Of the 209 (15.2%) adult patients with reports of adverse reactions of neutropenia, 19 patients discontinued b
Eintrag öffnenBosulif · 4.8 · Of the 472 (34.4%) adult patients with reports of adverse reactions of thrombocytopenia, 42 patients discontin
Eintrag öffnenBosulif · 4.8 · Paediatric populations
Eintrag öffnenBosulif · 4.8 · Renal disorders In patients with newly-diagnosed- CP CML treated with 400 mg, the median decline from baseline
Eintrag öffnenBosulif · 4.8 · Renal disorders In the paediatric study, 45 (82%) of the total 55 patients had normal eGFR (≥ 90 mL/min/1.73 m
Eintrag öffnenBosulif · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenBosulif · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenBosulif · 4.8 · Seven patients (0.5%) experienced QTcF prolongation (greater than 500 ms). Eleven (0.8%) patients experienced
Eintrag öffnenBosulif · 4.8 · Summary of safety profile
Eintrag öffnenBosulif · 4.8 · Table 4 – Adverse reactions for bosutinib
Eintrag öffnenBosulif · 4.8 · These adverse reactions are presented by system organ class and frequency. Frequency categories are defined as
Eintrag öffnen